Literature DB >> 455574

Features and prognosis of chemotherapy-treated Hodgkin's disease with initial bone marrow involvement.

G Auclerc, M F Auclerc, M Weil, J M Andrieu, C Jacquillat, J Bernard.   

Abstract

The features and prognosis of Hodgkin's disease with bone marrow involvement were studied in a series of 53 patients. This form of the disease is characterized by the high incidence of clinical and biological signs reflecting disease activity, common cytopenia (which is rare in other forms), an increased incidence of the lymphocyte depletion histologic type, and extensive lymphoid involvement, often with splenomegaly. In bone marrow biopsy specimens, Sternberg-Reed cells are found in 80% of cases and fibrosis is common, though it always disappears if remission is achieved. Chemotherapy, essentially with the MOPP combination, produced an 82% remission rate with 44% complete remission (CR). Hematologic toxicity was relatively severe in patients with marrow fibrosis. Recurrence occurred in 14 of the 39 remissions and was either localized and successfully treated by complementary radiotherapy, or diffuse and beyond any form of therapy. In nine cases, the first sign of recurrence was observed in the lymph node group initially most affected. Among the 18 patients treated by reinduction chemotherapy, four recurrences were observed. However, there was only one recurrence among the 12 patients who achieved CR and none among those who had received complementary radiotherapy. The long-term prognosis is similar to that of other visceral forms, and if CR is achieved the chance of maintaining the remission is 83% after the first year, with a follow-up exceeding 6 years.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 455574     DOI: 10.1007/bf00258294

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Hodgkin's disease in the bone marrow.

Authors:  R B Weiss; R D Brunning; B J Kennedy
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

2.  Chemotherapy as a primary treatment of Hodgkin's disease (204 new cases, 1 to 8 years of follow-up).

Authors:  C Jacquillat; M Weil; G Auclerc; J P Desprez-Curely; C Chastang; C Garçon; J P Chantalou; M F Gemon-Auclerc; J Delobel; M Dana; J Tanzer; F Teillet; V Izrael; N Chelloul; C Weisgerber; M De Heaulme; M Boiron; J Bernard
Journal:  Eur J Cancer       Date:  1975-10       Impact factor: 9.162

3.  Familial Hodgkin's disease: its significance and implications.

Authors:  D V RAZIS; H D DIAMOND; L F CRAVER
Journal:  Ann Intern Med       Date:  1959-11       Impact factor: 25.391

4.  Hodgkin's disease: an analysis of frequency, distribution and mortality at the University of California Hospital 1914-1951.

Authors:  M B SHIMKIN; K C OPPERMANN; W L BOSTICK; B V LOW-BEER
Journal:  Ann Intern Med       Date:  1955-01       Impact factor: 25.391

5.  Status and perspectives in chemotherapy of Hodgkin's disease.

Authors:  E Frei
Journal:  Arch Intern Med       Date:  1973-03

6.  Report of the Committee on Histopathological Criteria Contributing to Staging of Hodgkin's Disease.

Authors:  H Rappaport; C W Berard; J J Butler; R F Dorfman; R J Lukes; L B Thomas
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

7.  Bone-marrow biopsy in Hodgkin's disease.

Authors:  J M Bennett; H R Gralnick; V T Devita
Journal:  N Engl J Med       Date:  1968-05-23       Impact factor: 91.245

8.  Importance of bone marrow biopsy in the clinical staging of Hodgkin's disease.

Authors:  D I Webb; G Ubogy; R T Silver
Journal:  Cancer       Date:  1970-08       Impact factor: 6.860

9.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

10.  [Chemotherapy of Hodgkin's disease with drug combinations].

Authors:  C Jacquillat; M Weil; A Goguel; G Schaison; J Delobel; M F Gemon; R Brunel-Kotschi; F Teillet; M Boiron; J Bernard
Journal:  Presse Med       Date:  1971-03-06       Impact factor: 1.228

View more
  1 in total

1.  Prognostic factors in COPP-treated patients with Hodgkin's disease.

Authors:  W Gassmann; L Perenyi; N Schmitz; W Kayser; H Pralle; H Löffler
Journal:  Blut       Date:  1982-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.